MIAMI, FL, USA and JERUSALEM, Israel I July 08, 2025 I OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced ...

AdventHealth Avista, an Orthopedic and Spine Center of Excellence, conducted the first lumbar fusion procedure with PearlMatrix Bone Graft, the first and only ...

NEW YORK, NY, USA I July 8, 2025 I Myrtelle Inc. (“Myrtelle” or the “Company”), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, ...

LONDON, UK I July 09, 2025 I Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

Nature–evolved chemistry, human insight, and AI converge to advance a new generation of brain and mental health medicines ...

Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias – YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline o ...

SAN DIEGO, CA, USA I July 08, 2025 I Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote ...

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 Diabetes toward cGMP manufacturing and first-in-human clinical trials Strengthening the ...

Enabling efficient nose-to-brain drug delivery, MetP® offers an alternative to injection-based administration - targeting a $150 billion obesity and ...

HYOGO, Japan I July 8, 2025 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, ...